News

  • 11 October 2011

    Paladin Labs acquires Labopharm

    Canadian speciality pharmaceutical company Paladin Labs has completed the acquisition of all outstanding common shares of Labopharm.

  • 10 October 2011

    FDA clears Merck type 2 diabetes medication

    The US Food and Drug Administration (FDA) has approved Merck's Juvisync, a once-daily therapy for type 2 diabetes that combines glucose-lowering medication sitagliptin, the active component of Januvia, with cholesterol-lowering...

  • 9 October 2011

    CytRx reports preliminary efficacy results of bafetinib

    The CytRx ENABLE Phase II clinical trial has demonstrated positive results for bafetinib, a Bcr-Abl, Lyn and Fyn kinase inhibitor for the treatment relapsed or refractory B-cell chronic lymphocytic leukaemia...

  • 6 October 2011

    Santaris to report miravirsen drug trial results

    Santaris Pharma is set to release new clinical data results from the Phase 2a study of miravirsen, the microRNA-targeted drug designed to treat Hepatitis C virus (HCV) infected patients.

Go Top